163 related articles for article (PubMed ID: 38682116)
1. Preparation and evaluation of the PD0721‑DOX antibody‑drug conjugate targeting EGFRvIII to inhibit glioblastoma.
Hu M; Liu H; Zhang Y; Lu D; Zheng L; Wang Y; Chen S; Liu T
Exp Ther Med; 2024 Jun; 27(6):254. PubMed ID: 38682116
[TBL] [Abstract][Full Text] [Related]
2. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER
J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
[TBL] [Abstract][Full Text] [Related]
4. Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.
Ellwanger K; Reusch U; Fucek I; Knackmuss S; Weichel M; Gantke T; Molkenthin V; Zhukovsky EA; Tesar M; Treder M
Front Oncol; 2017; 7():100. PubMed ID: 28596941
[TBL] [Abstract][Full Text] [Related]
5. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
Hamblett KJ; Kozlosky CJ; Siu S; Chang WS; Liu H; Foltz IN; Trueblood ES; Meininger D; Arora T; Twomey B; Vonderfecht SL; Chen Q; Hill JS; Fanslow WC
Mol Cancer Ther; 2015 Jul; 14(7):1614-24. PubMed ID: 25931519
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
7. [Establishment and optimization of an ELISA for affinity detection of single-chain antibodies to EGFRvIII].
Zhang Y; Wu Z; He B; Yang C; Li Y; Liu T
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jan; 37(1):73-78. PubMed ID: 33441231
[TBL] [Abstract][Full Text] [Related]
8. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
10. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface.
Balyasnikova IV; Franco-Gou R; Mathis JM; Lesniak MS
J Tissue Eng Regen Med; 2010 Jun; 4(4):247-58. PubMed ID: 19937911
[TBL] [Abstract][Full Text] [Related]
11. A conjugate of an anti-midkine single-chain variable fragment to doxorubicin inhibits tumor growth.
Zhao S; Zhao G; Xie H; Huang Y; Hou Y
Braz J Med Biol Res; 2012 Mar; 45(3):230-7. PubMed ID: 22267001
[TBL] [Abstract][Full Text] [Related]
12. The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
Poźniak M; Porębska N; Krzyścik MA; Sokołowska-Wędzina A; Jastrzębski K; Sochacka M; Szymczyk J; Zakrzewska M; Otlewski J; Opaliński Ł
Mol Med; 2021 May; 27(1):46. PubMed ID: 33962559
[TBL] [Abstract][Full Text] [Related]
13. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation.
Xavier S; Gopi Mohan C; Nair S; Menon KN; Vijayachandran LS
Int J Biol Macromol; 2019 Mar; 124():17-24. PubMed ID: 30471391
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
Sinkule JA; Rosen ST; Radosevich JA
Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554
[TBL] [Abstract][Full Text] [Related]
15. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.
Ma Z; He H; Sun F; Xu Y; Huang X; Ma Y; Zhao H; Wang Y; Wang M; Zhang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1929-1940. PubMed ID: 28536738
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
17. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
Chistiakov DA; Chekhonin IV; Chekhonin VP
Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
